Ulipristalacetát v léčbě děložní myomatózy – finální výsledky studie PEARL IV
| Title in English | Ulipristal acetate in the treatment ofmyomatous uterine-final results of the PEARL IV study |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Popularization text |
| MU Faculty or unit | |
| Citation | |
| Description | Authors introduce final results of the PEARL IV study, which have confirmed effectiveness and safety of ulipristal acetate (Esmya*, GedeonRichter) dosed 5 and 10 rng once a day during intermittent treatment of symptomatic uterine myo-mas. A double-blinded study with 451 patients was carried out. There were four twelve-week therapeutic cycles dosed as mentioned above. In this study, ulipristal acetate managed to control bleeding, make myomas smaller, relieve pain and increase the quality of life. The effectiveness of studied parameters, compared to the initial values, was also evident at times between cycles of treatment and three months after the treatment had ended. Both dosages of ulipristal acetate were well tolerated, and there was a high level of patients' compliance with the treatment. No differences in safety were detected including thoroughly monitored endometrial changes and laboratory parameters between the dosages. The recent approval of intermittent treatment with ulipristal acetate proves these results as a significant piece of information for doctors in clinical practice. |